Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the June and July 2025 reimbursement prices for the following products, to reflect an increase in their NHS list prices. To avoid pharmacy owners dispensing these products at a loss, DHSC has agreed
Read moreAs part of our Funding & Reimbursement Shorts series, Community Pharmacy England’s in-house Drug Tariff and funding experts have created a new video on the end of month submission process. For the end-of-month submission, pharmacy teams are required to declare the month’s dispensing activity by completing the FP34C form on the Manage Your Service (MYS) portal.
Read moreThe Department of Health and Social Care (DHSC) has today (22/08/2025) confirmed the following list of price concessions for August 2025: Drug Pack size Price concession Clarithromycin 125mg/5ml oral suspension 70 £5.54 Esomeprazole 20mg gastro-resistant capsules 28 £4.23 Esomeprazole 40mg gastro-resistant capsules 28 £2.56 Ferrous gluconate 300mg tablets 28 £2.05 Ivabradine 7.5mg tablets 56 £3.17 Latanoprost
Read moreMHRA Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets (Chanelle Medical Unlimited Company) Drug alert number: EL(25)A/41 Date issued: 21 August 2025 Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on certain batches of Fexofenadine Hydrochloride 120mg film-coated
Read moreThe Department of Health and Social Care (DHSC) has today (19/08/2025) confirmed the following initial list of price concessions for August 2025: Drug Pack size Price concession Alfuzosin 2.5mg tablets 60 £7.22 Clarithromycin 250mg/5ml oral suspension 70 £10.52 Cyclizine 50mg/1ml solution for injection ampoules 5 £4.01 Dutasteride 500microgram capsules 30 £2.88 Ibuprofen 600mg tablets 84 £9.38
Read moreMHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited) Date issued: 14 August 2025 Drug Alert Number: EL(25)A/40 Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information. DMRC reference number: DMRC-35838218 Marketing Authorisation
Read moreDapagliflozin 5mg and 10mg tablets will be moving from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. Currently, all branded and generically written prescriptions
Read moreThe Department of Health and Social Care (DHSC) has published details of its ongoing work and plans to improve the management of medicines supply issues. This includes a commitment to consulting on the introduction of pharmacist flexibilities to supply alternatives when a medicine is in short supply. The new policy paper, Managing a robust and
Read moreThe National Patient Prescription Tracking Service (NPPTS) enables patients to access and track their prescriptions online through the NHS App or their NHS account (by logging in on the NHS website). NPPTS is a feature of the Electronic Prescription Service (EPS) that utilises a combination of Spine and Pharmacy IT supplier systems’ information to provide item and
Read moreThe NHS Business Services Authority (NHSBSA) has seen an increase in the number of prescriptions from patients using the “HRT only prescription prepayment certificate” prescription charge exemption category for products that are not covered by the HRT Prescription Prepayment Certificate (HRT PPC). In the 12 months between June 2024 and May 2025, the NHSBSA received over 200k
Read more
